Adial Pharmaceuticals Liabilities 2024

Adial Pharmaceuticals Aktienanalyse

What does Adial Pharmaceuticals do?

Adial Pharmaceuticals Inc was founded in 2010 in Charlottesville, Virginia. The company focuses on the discovery and development of drugs for the treatment of addiction disorders such as alcohol and nicotine dependence. Adial's business model is based on the belief that current therapies for addiction disorders are insufficient and that there is a need for more targeted and effective medications. The company develops drugs that target specific biological processes in the brain associated with addiction disorders. Adial has several divisions, including research and development, manufacturing, and clinical studies. The company has a promising pipeline of candidate molecules in various stages of development. The flagship product of Adial is AD04, which was developed for the treatment of alcohol dependence. AD04 is based on a novel approach called genetic prediction. It targets a specific biological process known as the opioid receptor and blocks it to reduce the craving for alcohol. Adial has recently completed a Phase 3 clinical trial with AD04, which has yielded promising results. The results suggest that AD04 is effective in reducing alcohol consumption in people with the genetic prediction. Adial plans to market AD04 in the USA and Europe. Adial also has a collaboration with the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the USA. This collaboration focuses on the development of drugs for the treatment of nicotine dependence. Adial has developed a promising molecule candidate that is currently being tested in Phase 2 clinical trials. Adial also has a division for manufacturing and technology partnerships. The company collaborates with various stakeholders in the pharmaceutical and biotech industry to develop technological solutions that can accelerate the development of new drugs. Overall, Adial Pharmaceuticals has focused on the discovery and development of drugs for the treatment of addiction disorders. The company has a promising pipeline of candidate molecules and has completed clinical trials with its flagship product AD04. Adial is also working in collaboration with renowned institutions such as NIDA of the NIH to expand the scope of its research and development. Adial Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Adial Pharmaceuticals's Liabilities

Adial Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Adial Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Adial Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Adial Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Adial Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Adial Pharmaceuticals stock

What is the level of liabilities of Adial Pharmaceuticals this year?

Adial Pharmaceuticals has a debt balance of 653,079.99 USD this year.

What were the liabilities of Adial Pharmaceuticals compared to the previous year?

The liabilities of Adial Pharmaceuticals have increased by -73.45% dropped compared to the previous year.

What are the consequences of high debt for investors of Adial Pharmaceuticals?

High liabilities can pose a risk for investors of Adial Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Adial Pharmaceuticals?

Low liabilities mean that Adial Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Adial Pharmaceuticals affect the company?

An increase in liabilities of Adial Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Adial Pharmaceuticals affect the company?

A decrease in the liabilities of Adial Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Adial Pharmaceuticals?

Some factors that can influence the liabilities of Adial Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Adial Pharmaceuticals so important for investors?

The liabilities of Adial Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Adial Pharmaceuticals take to modify the liabilities?

To change its liabilities, Adial Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Adial Pharmaceuticals pay?

Over the past 12 months, Adial Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adial Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adial Pharmaceuticals?

The current dividend yield of Adial Pharmaceuticals is .

When does Adial Pharmaceuticals pay dividends?

Adial Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adial Pharmaceuticals?

Adial Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adial Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adial Pharmaceuticals located?

Adial Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adial Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adial Pharmaceuticals from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Adial Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Adial Pharmaceuticals in the year 2023?

In the year 2023, Adial Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adial Pharmaceuticals pay out the dividend?

The dividends of Adial Pharmaceuticals are distributed in USD.